

# Frederick R Ueland

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7761901/publications.pdf>

Version: 2024-02-01

46  
papers

998  
citations

623574

14  
h-index

454834

30  
g-index

46  
all docs

46  
docs citations

46  
times ranked

1170  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Effectiveness of a Multivariate Index Assay in the Preoperative Assessment of Ovarian Tumors. <i>Obstetrics and Gynecology</i> , 2011, 117, 1289-1297.  | 1.2 | 202       |
| 2  | A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENAâ€“MONO/GOG-3020/ENGOT-ov45). <i>Journal of Clinical Oncology</i> , 2022, 40, 3952-3964.  | 0.8 | 125       |
| 3  | Long-Term Survival of Women With Epithelial Ovarian Cancer Detected by Ultrasonographic Screening. <i>Obstetrics and Gynecology</i> , 2011, 118, 1212-1221.   | 1.2 | 102       |
| 4  | First International Consensus Report on Adnexal Masses: Management Recommendations. <i>Journal of Ultrasound in Medicine</i> , 2017, 36, 849-863.   | 0.8 | 72        |
| 5  | CCNE1 Amplification as a Predictive Biomarker of Chemotherapy Resistance in Epithelial Ovarian Cancer. <i>Diagnostics</i> , 2020, 10, 279.  | 1.3 | 59        |
| 6  | Clinical performance of a multivariate index assay for detecting early-stage ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2014, 210, 78.e1-78.e9.   | 0.7 | 41        |
| 7  | Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma. <i>Gynecologic Oncology</i> , 2017, 145, 78-87.  | 0.6 | 31        |
| 8  | Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells. <i>Diagnostics</i> , 2020, 10, 121.   | 1.3 | 30        |
| 9  | Tumor-Associated Macrophages and Ovarian Cancer: Implications for Therapy. <i>Cancers</i> , 2022, 14, 2220.   | 1.7 | 30        |
| 10 | Serial ultrasonographic evaluation of ovarian abnormalities with a morphology index. <i>Gynecologic Oncology</i> , 2014, 135, 8-12.   | 0.6 | 29        |
| 11 | Survival of Women With Type I and II Epithelial Ovarian Cancer Detected by Ultrasound Screening. <i>Obstetrics and Gynecology</i> , 2018, 132, 1091-1100.   | 1.2 | 25        |
| 12 | Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2018, 149, 525-530. | 0.6 | 24        |
| 13 | Recurrence, death, and secondary malignancy after ovarian conservation for young women with early-stage low-grade endometrial cancer. <i>Gynecologic Oncology</i> , 2019, 155, 39-50.   | 0.6 | 16        |
| 14 | Survival outcome of women with stage IV uterine carcinosarcoma who received neoadjuvant chemotherapy followed by surgery. <i>Journal of Surgical Oncology</i> , 2018, 117, 488-496.   | 0.8 | 15        |
| 15 | The effect of ovarian imaging on the clinical interpretation of a multivariate index assay. <i>American Journal of Obstetrics and Gynecology</i> , 2014, 211, 65.e1-65.e11.   | 0.7 | 14        |
| 16 | Significance of venous thromboembolism in women with uterine carcinosarcoma. <i>Gynecologic Oncology</i> , 2018, 148, 267-274.  | 0.6 | 14        |
| 17 | Proposal for a Risk-Based Categorization of Uterine Carcinosarcoma. <i>Annals of Surgical Oncology</i> , 2018, 25, 3676-3684.   | 0.7 | 14        |
| 18 | Salvaging Detection of Early-Stage Ovarian Malignancies When CA125 Is Not Informative. <i>Diagnostics</i> , 2021, 11, 1440.   | 1.3 | 14        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Utilizing Patient-Derived Epithelial Ovarian Cancer Tumor Organoids to Predict Carboplatin Resistance. <i>Biomedicines</i> , 2021, 9, 1021.  | 1.4 | 13        |
| 20 | Characterizing sarcoma dominance pattern in uterine carcinosarcoma: Homologous versus heterologous element. <i>Surgical Oncology</i> , 2018, 27, 433-440.  | 0.8 | 12        |
| 21 | Prospective validation of an intraoperative algorithm to guide surgical staging in early endometrial cancer. <i>Gynecologic Oncology</i> , 2017, 145, 50-54.   | 0.6 | 11        |
| 22 | Disease-Specific Survival of Type I and Type II Epithelial Ovarian Cancers—Stage Challenges Categorical Assignments of Indolence & Aggressiveness. <i>Diagnostics</i> , 2020, 10, 56.  | 1.3 | 11        |
| 23 | Preclinical Evaluation of Artesunate as an Antineoplastic Agent in Ovarian Cancer Treatment. <i>Diagnostics</i> , 2021, 11, 395.   | 1.3 | 11        |
| 24 | DACH1 mutation frequency in endometrial cancer is associated with high tumor mutation burden. <i>PLoS ONE</i> , 2020, 15, e0244558.  | 1.1 | 10        |
| 25 | Salvage chemotherapy with taxane and platinum for women with recurrent uterine carcinosarcoma. <i>Gynecologic Oncology</i> , 2017, 147, 565-571.   | 0.6 | 9         |
| 26 | Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer. <i>PLoS ONE</i> , 2021, 16, e0254205.  | 1.1 | 9         |
| 27 | Clinical Factors Associated with Longer Hospital Stay Following Ovarian Cancer Surgery. <i>Healthcare (Switzerland)</i> , 2019, 7, 85.   | 1.0 | 8         |
| 28 | Mithramycin and Analogs for Overcoming Cisplatin Resistance in Ovarian Cancer. <i>Biomedicines</i> , 2021, 9, 70.  | 1.4 | 7         |
| 29 | Real-World Evaluation of Universal Germline Screening for Cancer Treatment-Relevant Pharmacogenes. <i>Cancers</i> , 2021, 13, 4524.  | 1.7 | 6         |
| 30 | Significance of Lymphovascular Space Invasion by the Sarcomatous Component in Uterine Carcinosarcoma. <i>Annals of Surgical Oncology</i> , 2018, 25, 2756-2766.  | 0.7 | 5         |
| 31 | Population-Based Analysis of Patient Age and Other Disparities in the Treatment of Ovarian Cancer in Central Appalachia and Kentucky. <i>Southern Medical Journal</i> , 2018, 111, 333-341.                                      | 0.3 | 5         |
| 32 | Clinical utility of CA-125 in the management of uterine carcinosarcoma. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e88.  | 1.0 | 4         |
| 33 | Ultrasonographic Visualization of the Ovaries to Detect Ovarian Cancer According to Age, Menopausal Status and Body Type. <i>Diagnostics</i> , 2022, 12, 128.  | 1.3 | 4         |
| 34 | Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study. <i>Journal of Clinical Oncology</i> , 0, , . | 0.8 | 4         |
| 35 | Factors Predicting Participation in the Prospective Genomic Sequencing Study, Total Cancer Care (TCC), in Kentucky. <i>Journal of Rural Health</i> , 2020, , .   | 1.6 | 3         |
| 36 | Survival Advantage Associated with Decrease in Stage at Detection from Stage IIIC to Stage IIIA Epithelial Ovarian Cancer. <i>Journal of Oncology</i> , 2014, 2014, 1-6.   | 0.6 | 2         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Uterine Corpus Malignancies in Appalachia Kentucky: Incidence, Survival, and Related Health Disparities. <i>Southern Medical Journal</i> , 2020, 113, 29-36.  | 0.3 | 2         |
| 38 | Characterization of Uterine Cervix Cancers in Women from Appalachian Kentucky. <i>Frontiers in Oncology</i> , 2021, 11, 808081.   | 1.3 | 2         |
| 39 | Tumor characteristics and outcome of uterine carcinosarcoma in women aged ≥80 years. <i>Surgical Oncology</i> , 2019, 29, 25-32.  | 0.8 | 1         |
| 40 | Significance of Pelvic Fluid Observed during Ovarian Cancer Screening with Transvaginal Sonogram. <i>Diagnostics</i> , 2022, 12, 144.   | 1.3 | 1         |
| 41 | The Log Odds of Positive Lymph Nodes Predict Survival of Advanced-Stage Endometrial Cancer: A Retrospective Analysis of 3230 Patients in the Surveillance, Epidemiology, and End Results Database. <i>Journal of Gynecologic Surgery</i> , 0, , . | 0.0 | 1         |
| 42 | Clinicopathological effects of body composition measurements for patients with endometrial cancer. <i>Minerva Ginecologica</i> , 2021, 72, 430-435.   | 0.8 | 0         |
| 43 | DACH1 mutation frequency in endometrial cancer is associated with high tumor mutation burden. , 2020, 15, e0244558.   |     | 0         |
| 44 | DACH1 mutation frequency in endometrial cancer is associated with high tumor mutation burden. , 2020, 15, e0244558.   |     | 0         |
| 45 | DACH1 mutation frequency in endometrial cancer is associated with high tumor mutation burden. , 2020, 15, e0244558.   |     | 0         |
| 46 | DACH1 mutation frequency in endometrial cancer is associated with high tumor mutation burden. , 2020, 15, e0244558.   |     | 0         |